Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...

"I am extremely proud that Takeda has been recognized as one of the top ten employers in the world for 2024. This confirms ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

Defending champion Yuka Saso's bid for a third U.S. Open title in five seasons got off to a rocky start with a 2-over-par 74.

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502 ...

US drugmaker Protagonist Therapeutics (Nasdaq: PTGX) and Japan’s Takeda Pharma (TYO:4502) announced detailed results from the ...

Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking ...